MUCOSOLV Capsule Ref.[50533] Active ingredients: Carbocisteine

MUCOSOLV CAPSULES must be used with caution in patients with a history of peptic ulcer or duodenal disease because of the risk that mucolytics may disrupt the gastric mucosal barrier.

No known interactions.

Safety in pregnancy and lactation has not been established.

MUCOSOLV CAPSULES have no or negligible influence on the ability to drive and use machines.

Immune system disorders

Frequency unknown: Anaphylactic reactions, allergic skin eruption and fixed drug eruption

Gastrointestinal disorders

Frequent: Nausea, diarrhoea, gastric discomfort

Less frequent: Gastro-intestinal bleeding

Frequency unknown: vomiting

Skin and subcutaneous tissue disorders

Less frequent: Skin rashes

Frequency unknown: allergic skin eruptions. Isolated cases of dermatitis bullous such as Stevens-Johnson syndrome and erythema multiforme have also been reported.

General disorders and administrative site conditions

Less frequent: Headache

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Health care providers are asked to report any suspected adverse reactions to SAHPRA via the “6.04 Adverse Drug Reactions Reporting Form”, found online under SAHPRA’s publications: https://www.sahpra.org.za/Publications/Index/8 and to Cipla Medpro (Pty) Ltd at drugsafetysa@cipla.com or telephone 080 222 6662 (toll free).

Not applicable.